Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Onconic Therapeutics (476060.KQ)
Seoul, KR
Onconic Therapeutics, Inc. operates as a biopharmaceutical enterprise, primarily dedicated to the discovery and advancement of novel therapeutic solutions. Its research and development initiatives principally focus on creating new medications for acid-related ailments and various oncological conditions. This company was established on May 7, 2020, and maintains its principal office in Seoul, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.16% | -9.50% | -10.35% | -18.94% | -8.19% | -4.08% | -13.41% | +10.12% | +10.12% | +10.12% | +10.12% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2025-12 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 1 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+259.8% ★ Q1'26: +150.6% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+135.1% ★ Q1'26: +221.2% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%+21.6% Q1'26: +14.7% (vs Q1'25)
-
EBIT margin Biotechnology: +0.0%+23.6% ★ Q1'26: +20.0% (vs Q1'25)
-
ROIC Biotechnology: -16.1%+65.0% ★ Q1'26: +81.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+444.3% Q1'26: +326.7% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.01× ★ Q1'26: 0.01× (vs Q1'25)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|
| Revenue |
53.39B
est: 54.00B (-1.1%)
|
88.50B
88.50B – 88.50B
+63.9% YoY
|
108.50B
108.50B – 108.50B
+22.6% YoY
|
| EBITDA |
13.15B
est: -23.88B (+155.1%)
|
-39.13B
-39.13B – -39.13B
-63.9% YoY
|
-47.98B
-47.98B – -47.98B
-22.6% YoY
|
| EBIT |
12.62B
est: -24.55B (+151.4%)
|
-40.23B
-40.23B – -40.23B
-63.9% YoY
|
-49.33B
-49.33B – -49.33B
-22.6% YoY
|
| Net Income |
15.78B
est: 14.06B (+12.3%)
|
119.06B
119.06B – 119.06B
+746.8% YoY
|
216.00B
216.00B – 216.00B
+81.4% YoY
|
| SGA |
28.25B
est: 126.92B (-77.7%)
|
208.00B
208.00B – 208.00B
+63.9% YoY
|
255.01B
255.01B – 255.01B
+22.6% YoY
|
| EPS |
358.67
est: 316.00 (+13.5%)
|
2,676.00
2,676.00 – 2,676.00
+746.8% YoY
|
4,855.00
4,855.00 – 4,855.00
+81.4% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-28 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-27 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-26 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-21 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-20 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-19 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-18 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-15 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-14 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-13 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-12 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-11 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-08 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-07 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-06 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-04 | B | 3/5 | 1/5 | 5/5 | 5/5 | 4/5 | 1/5 | 1/5 |
| 2026-04-30 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-28 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-27 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-24 | B | 3/5 | 1/5 | 5/5 | 5/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-23 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | B- | 3/5 | 1/5 | 5/5 | 5/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex Biotech 244580.KS | 2.08% | 2.98M | 0.45% |
| 2 | Goldman Sachs Innovate Equity ETF GINN | 0.03% | 69.0K | 0.50% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Hyunju Cha | Chief Scientific Officer | — | — |
| John Kim | Chief Executive Officer | — | male |
| Jongkil Shin | Chief Financial Officer | — | — |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 476060.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
